Travere Therapeutics Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
20.02
-0.42
(-2.05%)
Volume:
1,260,672
52 week range:
6.01 - 25.29
Market Cap:
1.778B
Company Description:
Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.